Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma.
Anloague A, Sabol HM, Kaur J, Khan S, Ashby C, Schinke C, Barnes CL, Alturkmani F, Ambrogini E, Gundesen MT, Lund T, Amstrup AK, Andersen TL, Diaz-delCastillo M, Roodman GD, Bellido T, Delgado-Calle J. Anloague A, et al. Among authors: gundesen mt. Haematologica. 2024 Nov 28. doi: 10.3324/haematol.2024.286484. Online ahead of print. Haematologica. 2024. PMID: 39605211 Free article.
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease.
Lund T, Gundesen MT, Juul Vangsted A, Helleberg C, Haukås E, Silkjær T, Asmussen JT, Manuela Teodorescu E, Amdi Jensen B, Schmidt Slørdahl T, Nahi H, Waage A, Abildgaard N, Schjesvold F; Nordic Myeloma Study Group. Lund T, et al. Among authors: gundesen mt. Blood Cancer J. 2024 Apr 15;14(1):65. doi: 10.1038/s41408-024-01046-2. Blood Cancer J. 2024. PMID: 38622134 Free PMC article. No abstract available.
Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease.
Johansen M, Levring MB, Stokbro K, Diaz-delCastillo M, Khan AA, Wickstroem LA, Gundesen MT, Kristensen IB, Nyvold CG, Andersen MØ, Andersen TL, Abildgaard N, Lund T. Johansen M, et al. Among authors: gundesen mt. Cancers (Basel). 2023 Nov 25;15(23):5585. doi: 10.3390/cancers15235585. Cancers (Basel). 2023. PMID: 38067289 Free PMC article. Review.
Potential value of pre-planned imaging of bone disease in multiple myeloma.
Gundesen MT, Asmussen JT, Schjesvold F, Vangsted AJ, Helleberg C, Haukås E, Silkjær T, Teodorescu EM, Jensen BA, Slørdahl TS, Nahi H, Waage A, Abildgaard N, Lund T; Nordic Myeloma Study Group. Gundesen MT, et al. Blood Cancer J. 2023 Jul 7;13(1):105. doi: 10.1038/s41408-023-00880-0. Blood Cancer J. 2023. PMID: 37419876 Free PMC article. No abstract available.
Increased Bone Volume by Ixazomib in Multiple Myeloma: 3-Month Results from an Open Label Phase 2 Study.
Diaz-delCastillo M, Gundesen MT, Andersen CW, Nielsen AL, Møller HEH, Vinholt PJ, Asmussen JT, Kristensen IB, Nyvold CG, Abildgaard N, Levin Andersen T, Lund T. Diaz-delCastillo M, et al. Among authors: gundesen mt. J Bone Miner Res. 2023 May;38(5):639-649. doi: 10.1002/jbmr.4807. Epub 2023 Apr 12. J Bone Miner Res. 2023. PMID: 36970780 Free article. Clinical Trial.
High levels of c-Met is associated with poor prognosis in glioblastoma.
Petterson SA, Dahlrot RH, Hermansen SK, K A Munthe S, Gundesen MT, Wohlleben H, Rasmussen T, Beier CP, Hansen S, Kristensen BW. Petterson SA, et al. Among authors: gundesen mt. J Neurooncol. 2015 May;122(3):517-27. doi: 10.1007/s11060-015-1723-3. Epub 2015 Mar 24. J Neurooncol. 2015. PMID: 25800004